We studied the differentiation profiles of B cell precursors
Pediatric bone marrow (BM) samples (n = 44) were obtained ecules, the stage-specific patterns were found to differ in cerfrom children undergoing diagnostic BM aspiration for the fol- 12 years). The two patients with the shortest follow-up (1 and 2 months) have been in conIntroduction firmed remission for 3 3 12 years and 4 months, respectively. All leukemia/lymphoma patients described in this paper were The mainstays in defining the phenotypic patterns of B cell treated according to BFM (Berlin-Frankfurt-Mü nster) treatdifferentiation have already been documented during the last ment protocols. In brief, for ALL a multi-agent induction thertwo decades. [1] [2] [3] [4] In brief, the CD19 antigen is expressed apy administered in three cycles over the first six months was throughout all stages of B cell maturation, 1,5 while CD10 is followed by a low-dose maintenance therapy until completion highly expressed in the most immature (CD34 + ) B cell precurof the second therapy year. All data concerning these patients sors (BCP), 3 and is lost at a later stage concomitantly with gain were obtained from the Austrian study center of the of surface expression of CD20, IgM and CD22. 2 More international BFM study group. recently, this classical model of B cell differentiation was challenged, as new antigenic patterns, 6-8 new insights into the sequence of antigen acquisition in B cell ontogeny, 9 and Antibodies tissue-related differences in the coordinate patterns of B lymphoid antigen expression were documented. 10, 11 In the present study, our aim was comprehensively to redeFluorescein isothiocyanate (FITC)-, and phycoerythrin (PE)-fine the phenotypic patterns of the early stages of normal B labeled, or unconjugated pure monoclonal antibodies cell differentiation in postnatal bone marrow by multi-(MoAbs) were used: CD7 (DK24-FITC), CD10 (SS2/36-PE), parameter flow cytometry. By comparing normal and postCD11a (MHM24 pure), CD19 (HD37-FITC, pure), CD20 (Bchemotherapy bone marrow, we focused on sample-inherent Ly1-FITC), CD44 (DF1485 pure) and CD45 (T29/33-FITC) differences in BCP phenotype and subset composition. Our were all from Dako (Glostrup, Denmark); CD34 (HPCA2-approach could be of particular interest for the development FITC, -PE) fom Becton Dickinson (BD; Sunnyvale, CA, USA); of techniques for immunologic residual disease investigations CD7 (3A1-RD1-PE) and CD45RA (2H4-RD1-PE, pure) from in B lineage acute lymphoblastic leukemia (ALL).
Coulter Figure 1 ). According to this subdivunconjugated MoAbs and then with biotinylated rabbit F(abЈ) 2 ision, any difference in the marker profiles of BCP from differanti-mouse Ig antibodies (from Dako). To exclude non-specific ent BM specimens could be attributed exclusively to differstaining via unsaturated binding sites of the second step ences in the subset composition. We found that specimens reagent, this was followed by incubation with unlabeled irrelof ALL patients in remission and regenerating after induction evant murine IgG 1 (MOPC21; Sigma, St Louis, MO, USA).
therapy, were reduced in their total B cell content, but had a Without washing, the directly labeled CD MoAbs were then considerable relative expansion of stage 1 BCP (Table 1) . added simultaneously and together with streptavidin-R670
Patients at the end of low-dose maintenance chemotherapy as (Gibco). Murine irrelevant isotype-matched fluorescent well as the non-leukemic probands (without any prior MoAbs as well as irrelevant F(abЈ) 2 fragments of rabbit Ig-FITC chemotherapy) showed a preponderance of more mature (all from Dako) were always included in the staining protocols stages. Due to the relatively small number of normal BM as negative controls. Incubations were performed at 4°C in donors, age-related differences were not assessed. the dark over 30 min and were followed by washing steps using PBS (0.13 mol/l NaCl, 7 mmol/l Na 2 HPO 4 , 3 mmol/l NaH 2 PO 4 ) with 2% FCS. Cellular permeabilization for the Phenotypic analysis of stage 1 BCP cells investigation of TdT and cytoplasmic -chain expression was performed using a commercially available formaldehyde-
The earliest B cells in the BM express CD10 and CD34. 3 In based erythrocyte lysing solution (BD) supplemented with Triaccordance, these markers were found on the corresponding ton-X (0.015%). The concentration of the latter had been BCP subsets in our analysis (stage 1). A majority of stage 1 titrated for optimal permeabilization together with a good cells typically displayed high levels of CD10 positivity (stage preservation of scattering and fluorescence properties. The 1B; Figure 2 , green subset). However, precursor cells (11.5% permeabilization step was always done after labeling of surmedian of total BCP 1; range 0-41%, n = 19) with considerface antigens. Prior to flow cytometry, cell suspensions were ably lower expression of CD10 were also observed ( for all these putative BCP subsets. were stored in listmode data files. Each conventional measure-CD7 has been shown to be expressed on rare subsets of ment contained 30 000 cells. For better definition of small CD34 + CD10 + lymphoid precursors in adult BM. 15 In convensubsets of cells, gated acquisition was performed for some tional experiments (n = 11 samples), no CD7 + CD34 + doublemarker combinations. Samples were first analyzed convenpositive cells could be observed. In gating experiments (n = 5 tionally, and using the same material, life gates were then set samples; correlating the markers CD34, CD7, CD19, CD10 in the appropriate fluorescence vs SSC correlations and gated and CD99), no CD7 reactivity reliably above background was events acquired to maximum yield (at least 10 000 events). All found on CD34 + CD10 + precursors in general (data not data were analyzed using the PAINT-A-GATE or the CELL shown). Quest software (BD).
CD20 was expressed at low or intermediate density on a considerable proportion of stage 1 cells (31.5% median; range 7-65%; Figure 3a CD34 and c seems to be a very rare event in normal B cell parallel. A median of 5.3% of BCP 1 cells expressed -chains in their cytoplasm (range 1.8-6.4%), whereas no reactivity differentiation, 16 we performed gated acquisition experiments on five samples. At least 10 000 CD34 + cells, counterstained was detected on the cell surface ( Table 2 ). The highest proportions of CD34 + c + cells were found in those two samples with CD19 and anti--heavy chain antibodies with (for c) or without (for s) prior permeabilization, were selectively with the highest proportion of BCP 1 cells relative to total B cells. Both samples were from patients in profound hematoacquired. Appropriate negative controls were always run in Table 1 Comparison of the BCP subset composition in the BM of ALL patients after hematopoietic regeneration from high-dose induction treatment as well as after low-dose maintenance therapy, and of probands without prior chemotherapy or bone marrow disease presented during the last 15 years. [1] [2] [3] [4] 10, 11 In certain details, substantial differences exist between these studies. Major topWith transition from stage 2 to stage 3, further changes in expression of several antigens were observed. Cells of the latics of discussion have been the sequence of acquisition of the earliest B lymphoid antigens CD10 and CD19, 1,2,4,9,24 as well ter, most mature stage ( Figure 3A ; red subset) displayed a gain in expression of the antigens CD45RA and especially CD20, as the coordinated phenotypic changes concerning the loss of CD10 expression in correlation with the sequence of acquiwhich were uniformly expressed at high density on all BCP 3. All stage 3 BCP were also s + . These phenotypic shifts were sition of the antigens CD20 and IgM. [2] [3] [4] 10, 11 Obviously, a significant deal of variation has been due to methodological intimately associated with a further reduction in CD10 density. We observed a continuous gradient of expression of issues (ie normal or leukemic samples as reference, two-or three-color investigations, affinity of the MoAbs used) as well expression of this antigen on stage 3 populations, suggestively reflecting the final loss of CD10 expression during this stage as to tissue-related differences in the proportions of BCP subpopulations at different maturational stages. (Figure 3b) . A median of 45% (range 6-84.5%, n = 14) of stage 3 cells were still CD10 + (violet subset in Figure 3b ). The Our observations are pertinent to these issues. The first major finding of our study is that normal and regenerating BM remaining stage 3 cells were negative for CD10 (red subset in Figure 3b ). Significantly (P Ͻ 0.02), CD10
+ stage 3 BCP were samples apparently differ in the subset composition of their B cell pool, with a preponderance of immature BCP in postmore numerous in the samples with higher proportions of more immature BCP cells. Considering a presumed differenchemotherapy specimens. There were, however, no differences between the two sample sources regarding stage-spetiation sequence from CD10
+ to CD10 − in stage 3, this could be interpreted as a 'shift to the left' in BCP 3 due to the cific phenotypic profiles of BCP. A second major observation is the considerable heterogeneity of the earliest stage of BCP. generation kinetics of the B cell pool in general.
The majority of these cells adhered to the well-characterized CD10 hi CD34 + CD19 + phenotype, 3 while CD34 + cells with lower CD10 expression were also found. Unequivocal B linStage-related differential expression of adhesion molecules on BCP subsets eage affiliation of the latter could be proved by virtue of CD19 expression in only two-thirds of this population. Importantly, these cell types could be observed not only in BM specimens We investigated the adhesion molecules CD11a, CD44, CD49d and CD49e, of which maturation-related differences from patients after chemotherapy, but also in normal controls. The data are in line with recent publications which showed in expression as well as major roles in B cell development and function have been reported, 17-21 as well as CD99, a that the proportion of CD10 + cells exceed those of CD19 + cells in adult BM samples enriched for early precursors. 15, 25 novel CD antigen involved in T cell adhesion processes.
22,23
Two general patterns of stage-related differential expression However, a lineage relationship of the majority of the CD10 lo CD34 + precursors, irrespective of CD19 expression, is were recognized (Figure 4) . Roughly, the surface density of the antigens CD11a and CD44 increased with maturation, while now suggested according to their uniform phenotypic appearance concerning CD99, TdT, and light scattering properties, that of CD49d, CD49e and CD99 decreased. Differences in expression of CD11a as well as CD49d on the three major as well as their generation kinetics. In order to confirm the B lineage affiliation of the CD19 − CD10 lo CD34 + precursors, we BCP stages were minor with broadly overlapping density pat- ance of CD10 and CD19, 2, 3, 24 as well as the precedence of that CD10 is lost prior to c expression. 3 We could demonstrate that CD20 and c already appear on a proportion of the CD19 have formerly been considered. 1, 4 A further major finding of our study is that CD10 broadly most immature BCP subset, which adds to the heterogeneity of stage 1. After transition to stage 2, which is still CD10 + , essenoverlaps in expression with CD20, c, and (to a lesser extent) s. Our observations contrast with the Loken model 2 of B cell tially all BCP cells were found to acquire c positivity. CD20 expression was far more variable in this subset, ranging from differentiation which considers that CD20 appears very late on postnatal BCP together with s, and also with the notion negative to relatively high levels. Such a desynchronized regu-motes our understanding of leukemia phenotypes as replicas 
